Investment Partners

Omni Innovation
Private Company

Eve Investments holds an approximate 40% stake in Omni Innovation. Omni Innovation creates unique and specialised medical nutrition products that can be used by people with chronic and lifestyle diseases. Omni's products are independently validated and supervised by Omni's expert collaborator network to ensure that customers have safe, effective and clinically tested products that provide benefit with scientific backing.

Omni Innovation has developed of a pre-meal drink for the dietary management of type 2 diabetes (T2D).  This flagship product, GlucoControlTM is a patented pre-meal drink which has been clinically shown to help manage T2D by reducing blood glucose spikes after meals.  In Australia the product is sold exclusively by Faulding® with GlucoControlTM distributed in up to 6,000 pharmacy outlets, as well as being available online through Terry White Chemmart.

In September 2017, Omni completed a distribution partnership with ASX listed Eagle Health Holdings for the Chinese market, for which Omni received an upfront payment of $1.5m, with $1m payable immediately and the balance on registration in the Chinese market.  The rollout of the product into the Chinese market commenced in December 2017 and is supported by Eagle establishing four diabetes education centres.

Eve is very excited with the potential of Omni’s growth profile and anticipates a listing event in the 2018/19 year.

 Please refer to the Omni Innovation website www.omniinnovation.com.au for further information.

Faulding launched a TV Commercial marketing campaign for Faulding® GlucoControlTM in late September.  The TV commercial can be viewed here.

Faulding® GlucoControlTM Dr. Ross Walker presented a segment on the benefits of Faulding® GlucoControlTM on the Nine Network’s Today Show, on 20 September - view here.

Keep up to date with Omni Innovation:        

 

  back to partners